Johnson & Johnson

Johnson & Johnson is an American multinational healthcare corporation that researches, develops, manufactures, and sells pharmaceuticals and medical devices across more than 175 countries, generating $94.2 billion in revenue in fiscal 2025. The company operates through two segments — Innovative Medicine (pharmaceuticals, roughly 64% of revenue) and MedTech (medical devices, roughly 36%) — fields 28 products and platforms each with more than $1 billion in annual sales, and employs approximately 140,800 people worldwide.

This is a story about breadth as a strategy in an industry where concentration risk is the norm. JNJ's portfolio spans oncology, immunology, neuroscience, cardiovascular devices, surgical robotics, orthopaedics, and vision care — a diversification that no pure-play pharmaceutical or medical-device company can replicate. The company is on track to exceed $100 billion in annual revenue for the first time in its 140-year history in fiscal 2026, a milestone that management has raised guidance toward and that the Q2 2026 results put within reach.

Yet the file is about transition, not scale. STELARA, a $10.4 billion immunology franchise as recently as FY2024, lost U.S. exclusivity in 2025 and fell 41% in a single year. SIMPONI biosimilars entered Europe in Q2 2026 and are pursuing U.S. approval. OPSUMIT generics reached the U.S. market in mid-2026. The IRA's drug price negotiation program has already selected four JNJ products for mandatory government pricing. Meanwhile, the company has spent over $18 billion on acquisitions in the past eighteen months — Intra-Cellular Therapies, Halda Therapeutics, and the pending Firefly Bio deal — and announced the separation of its $9.3 billion Orthopaedics unit. The central question is whether the growth portfolio JNJ is assembling can outrun the legacy erosion it is managing.